COMT polymorphism regulates the hippocampal subfield volumes in first-episode, drug-naive patients with major depressive disorder

Yuka Otsuka, Shingo Kakeda, Koichiro Sugimoto, Asuka Katsuki, Le Hoa Nguyen, Ryohei Igata, Keita Watanabe, Issei Ueda, Taro Kishi, Nakao Iwata, Yukunori Korogi, Reiji Yoshimura

Research output: Contribution to journalArticle

Abstract

Purpose: Compared with healthy subjects (HS), patients with major depressive disorder (MDD) exhibit volume differences that affect the volume changes in several areas such as the limbic, cortical, subcortical, and white matter. Catechol-O-methyltransferase (COMT) is a methylation enzyme that catalyzes endogenous catecholamines. The Val158Met polymorphism of COMT has been reported to affect the dopamine (DA) levels, which plays an important role in psychiatric diseases. However, the relationships among both DA levels, COMT genotype, and brain morphology are complicated and controversial. In previous studies that investigated the hippocampal subfields, the greatest brain abnormalities in MDD patients were observed in Cornu Ammonis (CA)1 and the subiculum, followed by that in CA2-3. We have prospectively demonstrated the relationship between the single-nucleotide polymorphism of the Val158Met COMT gene (rs4680) and the hippocampal subfields in drug-naive MDD patients. Patients and methods: In this study, we compared 27 MDD patients and 42 HS who were divided into groups based on their COMT genotype. The effects of the diagnosis, genotype, and genotype–diagnosis interaction related to CA1 and the subiculum volumes, as well as the whole-brain cortical thickness, were evaluated by performing a FreeSurfer statistical analysis of high-resolution magnetic resonance imaging (MRI) findings. Results: The results revealed that there was a statistically significant interaction between the effects of diagnosis and genotype on the right subiculum (a component of the hippocampus). Conclusion: This Val158Met COMT polymorphism may influence the subiculum volume in drug-naive, first-episode MDD patients.

Original languageEnglish
Pages (from-to)1537-1545
Number of pages9
JournalNeuropsychiatric Disease and Treatment
Volume15
DOIs
Publication statusPublished - 01-01-2019

Fingerprint

Catechol O-Methyltransferase
Major Depressive Disorder
Hippocampus
Genotype
Pharmaceutical Preparations
Dopamine
Healthy Volunteers
Brain
Methylation
Catecholamines
Single Nucleotide Polymorphism
Psychiatry
Magnetic Resonance Imaging
Enzymes
Genes

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Otsuka, Yuka ; Kakeda, Shingo ; Sugimoto, Koichiro ; Katsuki, Asuka ; Nguyen, Le Hoa ; Igata, Ryohei ; Watanabe, Keita ; Ueda, Issei ; Kishi, Taro ; Iwata, Nakao ; Korogi, Yukunori ; Yoshimura, Reiji. / COMT polymorphism regulates the hippocampal subfield volumes in first-episode, drug-naive patients with major depressive disorder. In: Neuropsychiatric Disease and Treatment. 2019 ; Vol. 15. pp. 1537-1545.
@article{416c6c78ea07401b912a3d00f8de5b32,
title = "COMT polymorphism regulates the hippocampal subfield volumes in first-episode, drug-naive patients with major depressive disorder",
abstract = "Purpose: Compared with healthy subjects (HS), patients with major depressive disorder (MDD) exhibit volume differences that affect the volume changes in several areas such as the limbic, cortical, subcortical, and white matter. Catechol-O-methyltransferase (COMT) is a methylation enzyme that catalyzes endogenous catecholamines. The Val158Met polymorphism of COMT has been reported to affect the dopamine (DA) levels, which plays an important role in psychiatric diseases. However, the relationships among both DA levels, COMT genotype, and brain morphology are complicated and controversial. In previous studies that investigated the hippocampal subfields, the greatest brain abnormalities in MDD patients were observed in Cornu Ammonis (CA)1 and the subiculum, followed by that in CA2-3. We have prospectively demonstrated the relationship between the single-nucleotide polymorphism of the Val158Met COMT gene (rs4680) and the hippocampal subfields in drug-naive MDD patients. Patients and methods: In this study, we compared 27 MDD patients and 42 HS who were divided into groups based on their COMT genotype. The effects of the diagnosis, genotype, and genotype–diagnosis interaction related to CA1 and the subiculum volumes, as well as the whole-brain cortical thickness, were evaluated by performing a FreeSurfer statistical analysis of high-resolution magnetic resonance imaging (MRI) findings. Results: The results revealed that there was a statistically significant interaction between the effects of diagnosis and genotype on the right subiculum (a component of the hippocampus). Conclusion: This Val158Met COMT polymorphism may influence the subiculum volume in drug-naive, first-episode MDD patients.",
author = "Yuka Otsuka and Shingo Kakeda and Koichiro Sugimoto and Asuka Katsuki and Nguyen, {Le Hoa} and Ryohei Igata and Keita Watanabe and Issei Ueda and Taro Kishi and Nakao Iwata and Yukunori Korogi and Reiji Yoshimura",
year = "2019",
month = "1",
day = "1",
doi = "10.2147/NDT.S199598",
language = "English",
volume = "15",
pages = "1537--1545",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

Otsuka, Y, Kakeda, S, Sugimoto, K, Katsuki, A, Nguyen, LH, Igata, R, Watanabe, K, Ueda, I, Kishi, T, Iwata, N, Korogi, Y & Yoshimura, R 2019, 'COMT polymorphism regulates the hippocampal subfield volumes in first-episode, drug-naive patients with major depressive disorder', Neuropsychiatric Disease and Treatment, vol. 15, pp. 1537-1545. https://doi.org/10.2147/NDT.S199598

COMT polymorphism regulates the hippocampal subfield volumes in first-episode, drug-naive patients with major depressive disorder. / Otsuka, Yuka; Kakeda, Shingo; Sugimoto, Koichiro; Katsuki, Asuka; Nguyen, Le Hoa; Igata, Ryohei; Watanabe, Keita; Ueda, Issei; Kishi, Taro; Iwata, Nakao; Korogi, Yukunori; Yoshimura, Reiji.

In: Neuropsychiatric Disease and Treatment, Vol. 15, 01.01.2019, p. 1537-1545.

Research output: Contribution to journalArticle

TY - JOUR

T1 - COMT polymorphism regulates the hippocampal subfield volumes in first-episode, drug-naive patients with major depressive disorder

AU - Otsuka, Yuka

AU - Kakeda, Shingo

AU - Sugimoto, Koichiro

AU - Katsuki, Asuka

AU - Nguyen, Le Hoa

AU - Igata, Ryohei

AU - Watanabe, Keita

AU - Ueda, Issei

AU - Kishi, Taro

AU - Iwata, Nakao

AU - Korogi, Yukunori

AU - Yoshimura, Reiji

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: Compared with healthy subjects (HS), patients with major depressive disorder (MDD) exhibit volume differences that affect the volume changes in several areas such as the limbic, cortical, subcortical, and white matter. Catechol-O-methyltransferase (COMT) is a methylation enzyme that catalyzes endogenous catecholamines. The Val158Met polymorphism of COMT has been reported to affect the dopamine (DA) levels, which plays an important role in psychiatric diseases. However, the relationships among both DA levels, COMT genotype, and brain morphology are complicated and controversial. In previous studies that investigated the hippocampal subfields, the greatest brain abnormalities in MDD patients were observed in Cornu Ammonis (CA)1 and the subiculum, followed by that in CA2-3. We have prospectively demonstrated the relationship between the single-nucleotide polymorphism of the Val158Met COMT gene (rs4680) and the hippocampal subfields in drug-naive MDD patients. Patients and methods: In this study, we compared 27 MDD patients and 42 HS who were divided into groups based on their COMT genotype. The effects of the diagnosis, genotype, and genotype–diagnosis interaction related to CA1 and the subiculum volumes, as well as the whole-brain cortical thickness, were evaluated by performing a FreeSurfer statistical analysis of high-resolution magnetic resonance imaging (MRI) findings. Results: The results revealed that there was a statistically significant interaction between the effects of diagnosis and genotype on the right subiculum (a component of the hippocampus). Conclusion: This Val158Met COMT polymorphism may influence the subiculum volume in drug-naive, first-episode MDD patients.

AB - Purpose: Compared with healthy subjects (HS), patients with major depressive disorder (MDD) exhibit volume differences that affect the volume changes in several areas such as the limbic, cortical, subcortical, and white matter. Catechol-O-methyltransferase (COMT) is a methylation enzyme that catalyzes endogenous catecholamines. The Val158Met polymorphism of COMT has been reported to affect the dopamine (DA) levels, which plays an important role in psychiatric diseases. However, the relationships among both DA levels, COMT genotype, and brain morphology are complicated and controversial. In previous studies that investigated the hippocampal subfields, the greatest brain abnormalities in MDD patients were observed in Cornu Ammonis (CA)1 and the subiculum, followed by that in CA2-3. We have prospectively demonstrated the relationship between the single-nucleotide polymorphism of the Val158Met COMT gene (rs4680) and the hippocampal subfields in drug-naive MDD patients. Patients and methods: In this study, we compared 27 MDD patients and 42 HS who were divided into groups based on their COMT genotype. The effects of the diagnosis, genotype, and genotype–diagnosis interaction related to CA1 and the subiculum volumes, as well as the whole-brain cortical thickness, were evaluated by performing a FreeSurfer statistical analysis of high-resolution magnetic resonance imaging (MRI) findings. Results: The results revealed that there was a statistically significant interaction between the effects of diagnosis and genotype on the right subiculum (a component of the hippocampus). Conclusion: This Val158Met COMT polymorphism may influence the subiculum volume in drug-naive, first-episode MDD patients.

UR - http://www.scopus.com/inward/record.url?scp=85069458973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069458973&partnerID=8YFLogxK

U2 - 10.2147/NDT.S199598

DO - 10.2147/NDT.S199598

M3 - Article

AN - SCOPUS:85069458973

VL - 15

SP - 1537

EP - 1545

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -